Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $81.00

Posted by Brian Himes on Nov 13th, 2026

Eton Pharmaceuticals (NASDAQ:ETON – Free Report) had its price objective raised by B. Riley Financial from $70.00 to $81.00 in a report released on Tuesday morning,Benzinga reports. B. Riley Financial currently has a buy rating on the stock.

Several other equities research analysts have also weighed in on ETON. HC Wainwright raised their target price on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Zacks Research raised Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Canaccord Genuity Group increased their price target on shares of Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Craig Hallum reissued a “buy” rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Finally, Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $79.75.

Check Out Our Latest Stock Analysis on ETON

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $61.45 on Tuesday. The company has a market cap of $1.77 billion, a P/E ratio of 40.70 and a beta of 0.89. The firm has a fifty day moving average price of $55.18 and a 200 day moving average price of $37.47. The company has a current ratio of 1.79, a quick ratio of 1.58 and a debt-to-equity ratio of 0.13. Eton Pharmaceuticals has a 12 month low of $14.27 and a 12 month high of $70.64.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19. The company had revenue of $57.93 million for the quarter, compared to analysts’ expectations of $41.98 million. Eton Pharmaceuticals had a return on equity of 104.82% and a net margin of 35.35%. Sell-side analysts predict that Eton Pharmaceuticals will post 1.54 earnings per share for the current fiscal year.

Insider Transactions at Eton Pharmaceuticals

In related news, insider David Krempa sold 4,166 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the sale, the insider directly owned 43,381 shares of the company’s stock, valued at $2,388,991.67. This represents a 8.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the transaction, the director owned 59,745 shares in the company, valued at $3,529,137.15. This represents a 45.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 82,666 shares of company stock worth $5,045,607. Corporate insiders own 16.49% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $26,000. Global Retirement Partners LLC purchased a new stake in Eton Pharmaceuticals in the 3rd quarter valued at $26,000. Morse Asset Management Inc purchased a new stake in Eton Pharmaceuticals in the 3rd quarter valued at $35,000. Toth Financial Advisory Corp acquired a new stake in Eton Pharmaceuticals during the 2nd quarter worth $43,000. Finally, Sterling Capital Management LLC boosted its stake in Eton Pharmaceuticals by 845.7% during the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after purchasing an additional 795 shares during the period. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

(Get Free Report)

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.